26.06.2015 • News

ADC Therapeutics Appoints Chris Martin as CEO

ADC Therapeutics announced the appointment of Dr Chris Martin as its CEO. Dr Martin was co-founder of Spirogen and its CEO leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca in October 2013. He continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. He will continue to advise Medimmune as a consultant.
Dr. Martin played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding. He replaces Michael Forer, CEO of the Company since its formation, who becomes vice chairman of ADC Therapeutics, and will continue to work with the company as executive vice president.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Top-Feature

most read